CO6241098A2 - Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formacion de la misma - Google Patents

Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formacion de la misma

Info

Publication number
CO6241098A2
CO6241098A2 CO09131818A CO09131818A CO6241098A2 CO 6241098 A2 CO6241098 A2 CO 6241098A2 CO 09131818 A CO09131818 A CO 09131818A CO 09131818 A CO09131818 A CO 09131818A CO 6241098 A2 CO6241098 A2 CO 6241098A2
Authority
CO
Colombia
Prior art keywords
biodegradable
glucose
poly
lactic
peptide
Prior art date
Application number
CO09131818A
Other languages
English (en)
Inventor
Hyun Hee Kwak
Ghun Ii Lee
Moohi Yoo
Soo Hyung Kang
Sung Hee Lee
Byong Moon Kim
Yoon Ji Kim
Tae Hyoung Kim
Hi Chang Yang
Mi Kyung Son
Yong Man Park
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of CO6241098A2 publication Critical patent/CO6241098A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se describen las microesferas biodegradablescapaces de liberar un péptido regulador de la glucosa deuna manera controlada, que comprende un portadorpolimérico biodegradable con el péptido regulador de laglucosa encapsulado en éste, y los métodos para lapreparación de las mismas. Además, para asegurar la altaeficiencia de encapsulamiento y la alta estabilidad delfármaco encapsulado, las microesferas no muestran unefecto inicial rápida ni tampoco liberación incompleta, ypermiten la liberación de orden cero de los fármacos en unperiodo prolongado, mejorando de este modo el efectoterapéutico del fármaco.1.- Una microesfera biodegradable capaz de liberar unpéptido regulador de la glucosa de una manera controlada,caracterizada porque comprende un portador poliméricobiodegradable con el péptido regulador de la glucosaencapsulado en éste.2.- La microesfera biodegradable de conformidad conla reivindicación 1, caracterizada porque el péptidoregulador de la glucosa se selecciona del grupo queconsiste de exendina-3 sintética, exendina-4 sintética, yhomólogos y agonistas de los mismos, sintéticos.3.- La microesfera biodegradable de conformidad conla reivindicación 2, caracterizada porque el péptidoregulador de la glucosa es exendina-4.4.- La microesfera biodegradable de conformidadcon la reivindicación 1, caracterizada porque el polímerobiodegradable se selecciona de un grupo que consiste deácido poli-L-láctico, ácido poli-D-láctico-ácido-co-glicólico,ácido poli-L-láctico-ácido-co-glicólico y ácido poli-D,L-láctico-ácido-co-glicólicc ácido.
CO09131818A 2007-04-19 2009-11-19 Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formacion de la misma CO6241098A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20070038467 2007-04-19

Publications (1)

Publication Number Publication Date
CO6241098A2 true CO6241098A2 (es) 2011-01-20

Family

ID=39875642

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09131818A CO6241098A2 (es) 2007-04-19 2009-11-19 Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formacion de la misma

Country Status (14)

Country Link
US (1) US8282990B2 (es)
EP (1) EP2139458A4 (es)
JP (1) JP5302952B2 (es)
KR (2) KR101034888B1 (es)
CN (1) CN101657190B (es)
AU (1) AU2008241699B2 (es)
BR (1) BRPI0810140A2 (es)
CA (1) CA2683698C (es)
CO (1) CO6241098A2 (es)
IL (1) IL201523A0 (es)
MX (1) MX2009011275A (es)
NZ (1) NZ580700A (es)
RU (1) RU2422134C1 (es)
WO (1) WO2008130158A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
CN102370624A (zh) * 2010-08-17 2012-03-14 东莞太力生物工程有限公司 Exendin-4缓释微球及其注射剂和该缓释微球的制备方法
US9675521B2 (en) 2010-09-02 2017-06-13 Nippon Kayaku Kabushiki Kaisha Process for producing drug-block copolymer composite and pharmaceutical preparation containing same
KR101785515B1 (ko) * 2010-11-08 2017-10-16 에스케이케미칼주식회사 올란자핀 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물
KR20120048811A (ko) * 2010-11-08 2012-05-16 에스케이케미칼주식회사 아나스트로졸 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
WO2013055791A1 (en) 2011-10-10 2013-04-18 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
WO2013074910A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
AR091478A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa)
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
AU2013323669B2 (en) 2012-09-26 2018-03-01 Indiana University Research And Technology Corporation Insulin analog dimers
RU2678134C2 (ru) 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты инсулин-инкретин
KR101486132B1 (ko) * 2013-03-20 2015-01-23 씨제이헬스케어 주식회사 졸-겔 변환 특성을 갖는 고분자를 이용한 미립구의 제조방법 및 이로부터 제조된 미립구
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
US10308719B2 (en) 2015-01-26 2019-06-04 The University Of Chicago IL13Rα2 binding agents and use thereof in cancer treatment
WO2017024111A1 (en) 2015-08-04 2017-02-09 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
WO2017053346A1 (en) 2015-09-21 2017-03-30 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
KR101706254B1 (ko) * 2015-11-17 2017-02-13 주식회사 동일팜텍 생체조직 수복 또는 재생용 고분자 미세입자의 제조방법
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
WO2019006235A1 (en) 2017-06-30 2019-01-03 Amgen Inc. METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS
EP3661954B1 (en) 2017-08-03 2022-02-09 Amgen Inc. Interleukin-21 muteins and methods of treatment
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
CN111565744A (zh) 2017-09-18 2020-08-21 加利福尼亚大学董事会 紧密连接蛋白6抗体和治疗癌症的方法
KR102047983B1 (ko) 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
CN111886031B (zh) * 2018-01-10 2022-10-14 G2G生物公司 含胶原蛋白肽的聚己内酯微球填充物及其制备方法
CR20210319A (es) 2018-01-12 2021-07-27 Amgen Inc ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)
KR102137786B1 (ko) * 2018-07-19 2020-07-24 주식회사 아울바이오 주사제용 미립구의 제조방법
RU2696773C1 (ru) * 2018-08-13 2019-08-06 Алексей Николаевич Осинцев Способ получения лекарственного препарата пептидной природы с контролируемым и последовательным высвобождением
WO2020055913A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of reducing- c-reactive protein and/or treating cardiovascular disease
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
CA3136496A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
CA3132656A1 (en) 2019-04-30 2020-11-05 Instituto De Medicina Molecular Joao Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
CA3140904A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
US20220280561A1 (en) 2019-08-30 2022-09-08 Research Institute At Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associted with mitochondrial dysfunction
KR102583029B1 (ko) * 2020-05-28 2023-09-26 주식회사 아울바이오 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
KR102469409B1 (ko) * 2020-08-24 2022-11-23 주식회사 메피온 색전물질 제조 방법
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
WO2022159575A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
WO2023281406A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
CN114588115B (zh) * 2022-04-20 2023-01-13 上海瑞凝生物科技有限公司 一种plga药物缓释微球的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
SE512663C2 (sv) * 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
ATE289205T1 (de) * 1998-12-15 2005-03-15 Takeda Pharmaceutical Verfahren zur herstellung biologisch-abbaubarer polyester
WO2001072323A2 (en) * 2000-03-24 2001-10-04 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
EP1296660A4 (en) * 2000-06-27 2005-04-13 Mi Tech Company Ltd PREPARATION FOR THE CONTROLLED RELEASE OF INSULIN AND ITS MANUFACTURING METHOD
CA2432904C (en) * 2000-12-21 2007-09-11 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophobic active agents
JP2003212758A (ja) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd 徐放性製剤の製造法
EP1369130A1 (en) * 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Process for producing sustained release preparation
KR100566573B1 (ko) * 2002-04-13 2006-03-31 주식회사 펩트론 Ｌｈｒｈ 동족체를 함유하는 서방성 미립구의 제조방법
CN102935069A (zh) 2003-07-15 2013-02-20 Pr药品有限公司 控释组合物的制备方法
PT1734971E (pt) * 2004-04-15 2012-02-02 Amylin Pharmaceuticals Inc Dispositivo de libertação sustentada baseado em polímero
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법

Also Published As

Publication number Publication date
RU2422134C1 (ru) 2011-06-27
CN101657190B (zh) 2013-09-11
EP2139458A4 (en) 2013-01-23
JP2010524924A (ja) 2010-07-22
CA2683698A1 (en) 2008-10-30
NZ580700A (en) 2012-01-12
AU2008241699B2 (en) 2011-02-03
IL201523A0 (en) 2010-05-31
CA2683698C (en) 2013-09-10
MX2009011275A (es) 2009-11-02
KR101034888B1 (ko) 2011-05-17
EP2139458A1 (en) 2010-01-06
AU2008241699A1 (en) 2008-10-30
WO2008130158A1 (en) 2008-10-30
US20100129459A1 (en) 2010-05-27
BRPI0810140A2 (pt) 2014-10-29
CN101657190A (zh) 2010-02-24
US8282990B2 (en) 2012-10-09
JP5302952B2 (ja) 2013-10-02
KR20110044192A (ko) 2011-04-28
KR20080094616A (ko) 2008-10-23
RU2009142608A (ru) 2011-05-27

Similar Documents

Publication Publication Date Title
CO6241098A2 (es) Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formacion de la misma
BR112015019546A2 (pt) implante de distribuição de drogas prolongado
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
EA201591560A1 (ru) Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
BR0107874A (pt) Implante farmacêutico para controlavelmente liberar uma droga, método para controlavelmente liberar uma droga em um indivìduo, e, método para preparar o implante
BR112018003882A2 (pt) material auxiliar para proporcionar eluição de fármaco de vasos
EA201491710A1 (ru) Препараты с контролируемым высвобождением для доставки ингибиторов hif-1
AR082384A1 (es) Particulas
PE20071139A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
AR064078A1 (es) Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion
BRPI0707044B8 (pt) comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
DE602005013244D1 (de) Pharmazeutische zusammensetzungen für die kontroll
AR100281A1 (es) Fertilizantes granulares recubiertos, métodos de preparación de los mismos, y usos
AR071239A1 (es) Microesferas que tienen una estructura de nucleo / recubrimiento que comprenden aripiprazol y uso
BR112014014599A2 (pt) polímeros de alfa-aminoamidina e uso dos mesmos
WO2015019213A4 (en) Microparticles having a multimodal pore distribution
CO2018005920A2 (es) Composiciones y métodos para fabricar micropartículas de proteína
AR072668A1 (es) Encapsulacion de agentes biologicamente activos
MX371139B (es) Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.
MX2016001607A (es) Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
JP2013505251A5 (es)
RU2012115120A (ru) Имплантируемые устройства, которые отличаются профилем высвобождения, и способы их изготовления и применения
EA201591111A1 (ru) Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида
BR112015019533A2 (pt) suporte polimérico de distribuição de uma substância naturalmente cristalina e método de produção do mesmo

Legal Events

Date Code Title Description
FC Application refused